ArticleMedicine2026
Gastric dose-volume parameters and toxicity in left-sided breast radiotherapy: A single-center retrospective comparison of helical tomotherapy and 3-dimensional field-in-field techniques.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During left-sided breast radiotherapy (LSBRT), several organs may be exposed to irradiation and develop treatment-related side effects. Compared with cardiopulmonary toxicity, gastric complications remain relatively under-investigated, although gastrointestinal complications are not uncommon in patients treated with LSBRT. This retrospective single-center study aimed to evaluate the relationship between gastric dose-volume parameters, gastric toxicity, and target volume coverage in patients treated with Helical Tomotherapy (HT) and 3-dimensional field-in-field (3D-FIF) techniques. Sixty-one patients treated with LSBRT were retrospectively analyzed, including 31 treated with HT and 30 with 3D-FIF. Dose-volume histograms were evaluated for target volumes (PTVbreast, PTVsupra, and PTVboost) and the stomach. For target coverage, Dmean, Dmin, Dmax, and D95% parameters were analyzed; for the stomach, Dmean, Dmax, D1cc, D10cc, V5Gy, and V10Gy parameters were analyzed. Reported gastric side effects and radiotherapy fractionation schemes were also evaluated. Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE v3.0). Comparisons between techniques were performed using appropriate statistical tests (IBM SPSS v27). The primary endpoint was the comparison of gastric dose-volume parameters and gastric toxicity. Patients treated with HT received significantly higher doses for all evaluated stomach dose parameters compared with those treated with 3D-FIF (P < .05). The incidence of gastric toxicity was also significantly higher in the HT group (P = .013). Notably, patients who developed gastric toxicity had significantly smaller stomach volumes (P = .015). Among patients receiving hypofractionated regimens, HT provided significantly higher D95% values for PTV coverage than 3D-FIF (P < .05), while no significant difference was observed in mean target doses. HT provided significantly improved target coverage, whereas 3D-FIF was associated with lower gastric dose and reduced gastric toxicity. Individualized technique selection based on patient-specific anatomical variations may help optimize both dosimetric and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.